A Swedish national post-marketing surveillance study of natalizumab treatment in multiple sclerosis

Multiple Sclerosis Journal

Volumn 17, Issue 6, 2011, Pages 708-719

  Holmén, Carolina ^a   Piehl, Fredrik ^a   Hillert, Jan ^a   Fogdell Hahn, Anna ^a   Lundkvist, Malin ^a   Karlberg, Elin ^a   Nilsson, Petra ^b   Dahle, Charlotte ^c   Feltelius, Nils ^d   Svenningsson, Anders ^e   Lycke, Jan ^f   Olsson, Tomas ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b LUND UNIVERSITY HOSPITAL   (Sweden)

^c Linköping Universitetssjukhus Department of Clinical and Experimental Medicine ^*  (Sweden)

^d MEDICAL PRODUCTS AGENCY   (Sweden)

^e UMEÅ UNIVERSITY   (Sweden)

^f UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

disease modifying therapies; multiple sclerosis; relapsing remitting; Tysabri

Indexed keywords

ANTIBODY; BETA1A INTERFERON; DACLIZUMAB; GLATIRAMER; IMMUNOGLOBULIN; INTERFERON BETA SERINE; METHYLPREDNISOLONE SODIUM SUCCINATE; MITOXANTRONE; NATALIZUMAB;

ACNE; ADOLESCENT; ADULT; ADVERSE OUTCOME; AGED; ALLERGIC REACTION; ALOPECIA; AMINOTRANSFERASE BLOOD LEVEL; ANAPHYLAXIS; ARTHRALGIA; ARTHRITIS; ARTICLE; ASTHENIA; BODY WEIGHT; BREAST ADENOCARCINOMA; BREAST CANCER; COLD; DIARRHEA; DISEASE SEVERITY; DIZZINESS; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; DRUG WITHDRAWAL; DYSARTHRIA; DYSPNEA; ECZEMA; EOSINOPHILIA; ERYTHEMA NODOSUM; EUPHORIA; EXPANDED DISABILITY STATUS SCALE; EYE INFLAMMATION; FATIGUE; FEMALE; FEVER; FLUSHING; HEART PALPITATION; HEART VENTRICLE FIBRILLATION; HEPATITIS C; HERPES SIMPLEX; HERPES ZOSTER; HUMAN; HYPERTENSION; INFLUENZA; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; MENINGITIS; MENSTRUATION DISORDER; MULTIPLE SCLEROSIS; MULTIPLE SCLEROSIS IMPACT SCALE; MULTIPLE SCLEROSIS SEVERITY SCALE; MYALGIA; NAUSEA; NEPHRITIS; NERVOUS SYSTEM INFLAMMATION; NEUROLOGIC EXAMINATION; NEUROPSYCHOLOGICAL TEST; NEUTROPENIA; OLIGOMENORRHEA; ONYCHOLYSIS; PNEUMONIA; POSTMARKETING SURVEILLANCE; PREGNANCY; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; PRURITUS; PSORIASIS; PSYCHOSIS; RATING SCALE; REGISTER; RESPIRATORY TRACT DISEASE; RHINITIS; SIDE EFFECT; SPONTANEOUS ABORTION; SUDDEN DEATH; SUICIDE; SUICIDE ATTEMPT; SWEDEN; SYMBOL DIGIT MODALITIES TEST; TACHYCARDIA; THORAX PAIN; TONSILLITIS; TREATMENT OUTCOME; URINARY TRACT INFECTION; URTICARIA; VOMITING;

EID: 79959452689     PISSN: 13524585     EISSN: 14770970     Source Type: Journal    
DOI: 10.1177/1352458510394701     Document Type: Article

References (28)

1. Brown BA. Natalizumab in the treatment of multiple sclerosis. Ther Clin Risk Manag. 2009 ; 5: 585-594
2. Polman CH, O'Connor PW, Havrdova E, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med. 2006 ; 354: 899-910
3. US Food and Drug Administration. Drug Safety and Availability. http://www.fda.gov/Drugs/DrugSafety/ (Information on natalizumab-marketed as Tysabri.) Updated information: September 2009.
4. Biogen Idec. Monthly Tysabri safety communication, May 2010, S.
5. Swedish MS Association. Rekommendationer avseende behandling av MS med natalizumab (Tysabri). http://www.mssallskapet.se/ October 2009 [In English: Swedish MS Association.. Recommendations regarding treatment of MS with natalizumab (Tysabri). http://www.mssallskapet.se/.].
6. Roxburgh RH, Seaman SR, Masterman T, et al. Multiple Sclerosis Severity Score: using disability and disease duration to rate disease severity. Neurology. 2005 ; 64: 1144-1151
7. Kurtzke JF. Clinical definition for multiple sclerosis treatment trials. Ann Neurol. 1994 ; 36 (Suppl.). S73 - S79
8. Hobart JC, Riazi A, Lamping DL, Fitzpatrick R, Thompson AJ. How responsive is the Multiple Sclerosis Impact Scale (MSIS-29)? A comparison with some other self report scales. J Neurol Neurosurg Psychiatry. 2005 ; 76: 1539-1543 (Pubitemid 41531702)
9. Riazi A, Hobart JC, Lamping DL, Fitzpatrick R, Thompson AJ. Multiple Sclerosis Impact Scale (MSIS-29): reliability and validity in hospital based samples. J Neurol Neurosurg Psychiatry. 2002 ; 73: 701-704 (Pubitemid 35448855)
10. Benedict RH, Duquin JA, Jurgensen S, et al. Repeated assessment of neuropsychological deficits in multiple sclerosis using the Symbol Digit Modalities Test and the MS Neuropsychological Screening Questionnaire. Mult Scler. 2008 ; 14: 940-946
11. Parmenter BA, Weinstock-Guttman B, Garg N, Munschauer F, Benedict RH. Screening for cognitive impairment in multiple sclerosis using the Symbol Digit Modalities Test. Mult Scler. 2007 ; 13: 52-57 (Pubitemid 46152761)
12. Yao K, Gagnon S, Akhyani N, et al. Reactivation of human herpesvirus-6 in natalizumab treated multiple sclerosis patients. PLoS One. 2008 ; 3: e2028 - e2028
13. TYSABRI-The TOUCH Prescribing Program, http://www.tysabri.com/ tysbProject/tysb.portal/.
14. Bezabeh S, Flowers CM, Kortepeter C and Avigan M. Clinically significant liver injury in patients treated with natalizumab. Aliment Pharmacol Ther 2010; 31(9): 1028-1035.
15. Linda H, von Heijne A, Major EO, et al. Progressive multifocal leukoencephalopathy after natalizumab monotherapy. N Engl J Med. 2009 ; 361: 1081-1087
16. Havrdova E, Galetta S, Hutchinson M, et al. Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study. Lancet Neurol. 2009 ; 8: 254-260
17. Mancardi GL, Amato MP, D'Alessandro R, et al. Natalizumab: a country-based surveillance program. Neurol Sci. 2008 ; 29 (Suppl. 2). S235 - S237
18. Tedeschi G, Amato MP, D'Alessandro R, et al. The pharmacovigilance program on natalizumab in Italy: 2 years of experience. Neurol Sci. 2009 ; 30 (Suppl. 2). S163 - S165
19. Oturai AB, Koch-Henriksen N, Petersen T, Jensen PE, Sellebjerg F, Sorensen PS. Efficacy of natalizumab in multiple sclerosis patients with high disease activity: a Danish nationwide study. Eur J Neurol. 2009 ; 16: 420-423
20. Putzki N, Kollia K, Woods S, Igwe E, Diener HC, Limmroth V. Natalizumab is effective as second line therapy in the treatment of relapsing remitting multiple sclerosis. Eur J Neurol. 2009 ; 16: 424-426
21. Outteryck O, Ongagna JC, Zephir H, et al. Demographic and clinic characteristics of French patients treated with natalizumab in clinical practice. J Neurol. 2010 ; 257: 207-211
22. Hobart J, Lamping D, Fitzpatrick R, Riazi A, Thompson A. The Multiple Sclerosis Impact Scale (MSIS-29): a new patient-based outcome measure. Brain. 2001 ; 124: 962-973 (Pubitemid 32458508)
23. Goodman AD, Rossman H, Bar-Or A, et al. GLANCE: results of a phase 2, randomized, double-blind, placebo-controlled study. Neurology. 2009 ; 72: 806-812
24. Calabresi PA, Giovannoni G, Confavreux C, et al. The incidence and significance of anti-natalizumab antibodies: results from AFFIRM and SENTINEL. Neurology. 2007 ; 69: 1391-1403 (Pubitemid 47511460)
25. TYSABRI (Natalizumab) Prescribing Information. Cambridge, MA: Biogen Idec Inc. ; 2008 :
26. Major EO. Reemergence of PML in natalizumab-treated patients-new cases, same concerns. N Engl J Med. 2009 ; 361: 1041-1043
27. Berger JR. Paradoxically aggressive multiple sclerosis in the face of natalizumab therapy. Mult Scler. 2008 ; 14: 708-710 (Pubitemid 351954417)
28. Stuve O, Cravens PD, Frohman EM, et al. Immunologic, clinical, and radiologic status 14 months after cessation of natalizumab therapy. Neurology. 2009 ; 72: 396-401